1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A multicenter, randomized, controlled trial comparing the occurrence of major adverse cardiovascular events (MACEs) in patients (pts) with prostate cancer (pc) and cardiovascular disease (CVD) receiving degarelix (GnRH receptor antagonist) or leuprolide (GnRH receptor agonist)
    Meeting Abstract

    Slovin, S. F.; Melloni, C.; Mansor-Lefebvre, S.; Neijber, A.; Roe, M.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Tumor mutational burden, clinical features, and outcomes to PD-1 mono- and combination therapy in patients with cutaneous and unknown primary melanoma
    Meeting Abstract

    Shoushtari, A. N.; Armenia, J.; Arora, A.; Rojas-Zamalloa, J.; Warner, A. B.; Derr, M.; Postow, M. A.; Callahan, M. K.; Momtaz, P.; Coit, D. G.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A phase II evaluation of nivolumab, a fully human antibody against PD-1, in the treatment of persistent or recurrent cervical cancer
    Meeting Abstract

    Santin, A.; Deng, W.; Frumovitz, M. M.; Huh, W. K.; Khleif, S.; Lankes, H. A.; Ratner, E.; O'Cearbhaill, R.; Jazaeri, A. A.; Birrer, M.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who have received PD-1 based therapy
    Meeting Abstract

    Saab, K.; Mooradian, M.; Wang, D. Y.; Chon, J.; Xia, C. Y.; Bialczak, A.; Abbate, K.; Menzies, A. M.; Johnson, D. B.; Sullivan, R. J.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Phase 1, multicenter, open-label study of single-agent bispecific antibody t-cell engager GBR 1342 in relapsed/refractory multiple myeloma
    Meeting Abstract

    Richter, J. R.; Landgren, C. O.; Kauh, J. S.; Back, J.; Salhi, Y.; Reddy, V.; Bayever, E.; Berdeja, J. G.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Histology of Rosai-Dorfman disease in a subset of patients with Erdheim-Chester disease: A distinct entity mainly driven by MAP2K1
    Meeting Abstract

    Razanamahery, J.; Diamond, E. L.; Plate, K.; Charlotte, F.; HeĢlias-Rodzewicz, Z.; Dogan, A.; Abdel-Wahab, O. I.; Durham, B. H.; Ozkaya, N.; Amoura, Z.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • AMC075: A randomized phase II trial of vorinostat with R-EPOCH in aggressive HIV-related NHL
    Meeting Abstract

    Ramos, J. C.; Sparano, J. A.; Moore, P. C.; Cesarman, E.; Reid, E. G.; Rubinstein, P. G.; Harrington, R. D.; Baiocchi, R. A.; Aboulafia, D. M.; Ratner, L.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma (HL): North American results
    Meeting Abstract

    Ramchandren, R.; Advani, R. H.; Ansell, S. M.; Bartlett, N. L.; Chen, R. W.; Feldman, T.; Forero-Torres, A.; Friedberg, J. W.; Gopal, A. K.; Gordon, L. I.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Ivosidenib (IVO; AG-120) in mutant IDH1 relapsed/refractory acute myeloid leukemia (R/R AML): Results of a phase 1 study
    Meeting Abstract

    Pollyea, D. A.; Dinardo, C. D.; de Botton, S.; Stein, E.; Roboz, G. J.; Mims, A. S.; Swords, R. T.; Altman, J. K.; Collins, R.; Mannis, G. N.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Projecting long term survival for avelumab in refractory Merkel cell carcinoma
    Meeting Abstract

    Phatak, H.; Proskorovsky, I.; Lanitis, T.; Ambavane, A.; Hunger, M.; D'Angelo, S. P.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save